**1-[[(5-bromo-2-furanyl)-oxomethyl]amino]-3-[(4-chlorophenyl)methyl]thiourea** is a complex organic compound with a unique structure containing several functional groups.
**Structure:**
* **Thiourea:** The core structure of the molecule is thiourea, a compound containing a sulfur atom and two amino groups.
* **(5-bromo-2-furanyl)-oxomethyl:** This moiety is an aldehyde group attached to a furan ring, which itself has a bromine atom.
* **(4-chlorophenyl)methyl:** This part of the molecule is a benzyl group with a chlorine atom attached to the phenyl ring.
**Importance in Research:**
This compound is likely important for research due to its combination of unique structural features and potential pharmacological activity. Here's why:
* **Potential Biological Activity:**
* **Thiourea:** Thiourea derivatives are known to exhibit various biological activities, including anti-inflammatory, antimicrobial, and anti-cancer properties.
* **Furan Ring:** Furan rings are common in natural products and synthetic drugs and often contribute to biological activity.
* **Halogenated Groups:** Halogenated groups (bromine and chlorine) can modify a molecule's properties, including lipophilicity, reactivity, and biological interactions.
* **Lead Compound:** The compound could serve as a lead compound for drug discovery. Researchers might modify this molecule by changing its substituents or creating analogs to explore potential therapeutic applications.
* **Chemical Probe:** It could be used as a chemical probe to study specific biological targets or pathways.
**Possible Areas of Research:**
Based on its structure, this compound could be investigated for its potential in:
* **Anti-inflammatory research:** Thiourea derivatives have anti-inflammatory properties, and the furan ring could enhance this effect.
* **Antimicrobial research:** The combination of the furan ring and halogenated groups might contribute to antimicrobial activity.
* **Cancer research:** Thiourea derivatives have shown anti-cancer properties, and the benzyl group could potentially enhance this effect.
**Important Note:** The specific research focus and importance of this compound will depend on the research goals of the scientists studying it. It's crucial to consult the relevant scientific publications to gain a comprehensive understanding of its significance.
ID Source | ID |
---|---|
PubMed CID | 2208880 |
CHEMBL ID | 1535882 |
CHEBI ID | 109364 |
Synonym |
---|
2-(5-bromo-2-furoyl)-n-(4-chlorobenzyl)hydrazinecarbothioamide |
MLS000666455 , |
smr000294277 |
2-[(5-bromofuran-2-yl)carbonyl]-n-(4-chlorobenzyl)hydrazinecarbothioamide |
STK455373 |
CHEBI:109364 |
AKOS003323607 |
1-[(5-bromofuran-2-carbonyl)amino]-3-[(4-chlorophenyl)methyl]thiourea |
HMS2676I20 |
bdbm46331 |
1-[(5-bromanylfuran-2-yl)carbonylamino]-3-[(4-chlorophenyl)methyl]thiourea |
cid_2208880 |
1-[[(5-bromo-2-furanyl)-oxomethyl]amino]-3-[(4-chlorophenyl)methyl]thiourea |
1-[(5-bromo-2-furoyl)amino]-3-(4-chlorobenzyl)thiourea |
CHEMBL1535882 |
Q27188472 |
SR-01000277436-1 |
sr-01000277436 |
Class | Description |
---|---|
furoic acid | A monocarboxylic acid that consists of a furan ring having a single carboxylic acid group on any ring position and derivatives thereof. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 0.7079 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 39.8107 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 10.0000 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 37.9330 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Rac1 protein | Homo sapiens (human) | EC50 (µMol) | 0.0857 | 0.0202 | 5.9860 | 29.5100 | AID1340 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |